New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 27, 2014
20:58 EDTNEPT, ACSTNeptune, Enzymotec conclude patent infringement settlement, license agreement
Neptune Technologies & Bioressources (NEPT) and Acasti Pharma (ACST), a Neptune subsidiary, announce that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec and Enzymotec USA, that resolves the International Trade Commission's, ITC, investigation of infringement of Neptune's composition of matter patents, related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review proceedings requested by Enzymotec. As part of the settlement, Neptune granted a world-wide, non-exclusive, royalty-bearing license to Enzymotec, allowing it to market and sell its nutraceutical products under Neptune's '348 family of patents. Under the terms of the settlement, royalty levels in the USA are dependent on the outcome of pending inter partes review proceedings before the U.S. Patent and Trademark Office, USPTO, regarding certain claims of Neptune's '351 composition of matter patent. Furthermore, royalty levels in Australia are dependent on a potential request by Enzymotec to the Australian Patent Office for a post-grant review of certain claims of Neptune's allowed composition of matter patent application. Enzymotec also agreed to pay Neptune a non-refundable one-time upfront settlement payment. The financial terms of the license are confidential between the parties.
News For NEPT;ACST From The Last 14 Days
Check below for free stories on NEPT;ACST the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
08:08 EDTACSTAcasti Pharma announces positive top-line pharmacokinetic results
Subscribe for More Information
September 29, 2014
08:10 EDTACSTAcasti Pharma reports CaPre Phase II trial met primary endpoint
Acasti Pharma announces successful top-line results for its Phase II double blind, placebo controlled trial, or TRIFECTA, assessing the safety and efficacy of CaPre for the treatment of patients with hypertriglyceridemia. CaPre, Acasti's investigational new drug candidate, is composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain cardiometabolic disorders. CaPre successfully met the trial's primary endpoint achieving a statistically significant mean placebo-adjusted decrease in triglycerides from baseline to week-12, with reductions of 36.4% for 1 gram and 38.6% for 2 grams.
September 23, 2014
08:22 EDTNEPTNeptune reaches annualized production capacity of 100 metric tons at Sherbrooke
Neptune Technologies announces that its Sherbrooke plant is now operating at an annualized production capacity of 100 metric tons and customer shipments of Neptune manufactured krill oil products have commenced.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use